Nexstim Oyj: Nexstim NBS system sold to the Jewish General Hospital in Canada

Press release, Helsinki, 28 May 2019 at 9.30 am (EET)

Nexstim NBS system sold to the Jewish General Hospital in Canada

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") - the targeted neuromodulation company developing and marketing pioneering, navigated, personalised, non-invasive brain stimulation systems for diagnostics and therapy - today announces that it has sold a NBS system in Canada to the Jewish General Hospital (CIUSS West-Central Montreal). The Jewish General Hospital is a teaching hospital affiliated with the renowned McGill University.

Nexstim's NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. The NBS system is used, for example, after a patient has had a diagnosis of a brain tumour or other disorder and when the lesion is thought to be close to functional areas of the brain - such as those responsible for speech production and limb movement. Brain maps from NBS can be invaluable when deciding the best treatment option for the patient.

Nexstim received the Medical Device Licence for its NBS system and NexSpeech from Health Canada in March 2019.

Martin Jamieson, Chairman and CEO of Nexstim PLC, said: "We are delighted to announce that after receiving the Medical Device Licence from the Canadian authorities earlier this year, we are now entering the Canadian market. Nexstim's NBS system is a unique mapping tool for neurosurgeons and neurologists: its clinical value has been clearly established in over 79 publications, covering its use in close to 3500 patients. "

Further information is available on the website www.nexstim.comor by contacting:

Nexstim
Martin Jamieson, Chairman and CEO
[phone]
[e-mail]

Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
[phone]
[e-mail]

About Nexstim Plc

Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBT system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit www.nexstim.com

Attachment

• Nexstim Press Release_NBS sales_Jewish General Hospital_EN_Final (https://ml-eu.globenewswire.com/Resource/Download/e9461628-189a-44e1-8a5a-e300dcbc1c9c)